Buy Opdivo (Nivolumab)
Price range: €420.00 through €865.00
Opdivo (nivolumab) is a drug used to treat certain types of cancer.
What is Opdivo (nivolumab) for?
Opdivo (nivolumab) is indicated for the treatment of patients with the following conditions:
- metastatic melanoma as monotherapy or in combination with ipilimumab
- metastatic non-small cell lung cancer (NSCLC) whose cancer has progressed during or after chemotherapy
- advanced renal cell carcinoma who have previously received anti-angiogenic therapy
- classical Hodgkin lymphoma that has relapsed or progressed after other treatments
- Recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC) with disease progression during or within 6 months of receiving platinum-based chemotherapy
- locally advanced, unresectable or metastatic urothelial carcinoma after progression under platinum-based therapy
- Metastatic colorectal cancer (mCRC) with high microsatellite instability (MSI-H) or mismatch repair-deficient (dMMR) that has progressed after treatment with a fluoropyrimidine, oxaliplatin and irinotecan
- hepatocellular carcinoma in patients previously treated with sorafenib
- for the adjuvant treatment of completely resected esophageal cancer or cancer of the gastroesophageal junction (GEJ) with persistent pathological residual disease in patients who have received neoadjuvant radiochemotherapy (CRT).
How does Opdivo (nivolumab) work?
Opdivo (nivolumab) is designed to bind to a receptor called PD-1, which is found on certain immune system cells called T cells. Cancer cells can produce proteins (PD-L1 and PD-L2) that bind to this receptor and shut down T cells. By binding to the receptor, nivolumab prevents cancer cells from shutting down T cells, thus increasing the immune system’s ability to kill cancer cells.
Is Opdivo (nivolumab) approved?
Opdivo (nivolumab) was approved by
- PMDA (Japan)
- in June 2014 for unresectable malignant melanoma
- on December 17, 2015 for NSCLC
- on August 5, 2016 for unresectable or metastatic renal cell carcinoma
- on October 17, 2016 for relapsed or refractory classical Hodgkin lymphoma
- on February 22, 2017 for recurrent or distant metastatic head and neck cancer
- on August 22, 2017 for unresectable advanced or recurrent gastric cancer that has progressed after cancer chemotherapy
- May 27, 2021 for unresectable advanced or recurrent malignant pleural mesothelioma.
- FDA (USA)
- on December 22, 2014 for unresectable or metastatic melanoma
- on March 4, 2015 for metastatic non-small cell lung cancer (NSCLC)
- on November 23, 2015 for advanced renal cell carcinoma
- on May 17, 2016 for classical Hodgkin lymphoma (cHL)
- on November 10, 2016 for squamous cell carcinoma of the head and neck (HNSCC)
- on February 2, 2017 for advanced inoperable or metastatic urothelial carcinoma
- on August 1, 2017 for metastatic colorectal cancer with high microsatellite instability (MSI-H) or mismatch repair deficient (dMMR)
- on September 22, 2017 for hepatocellular carcinoma (HCC) after prior treatment with sorafenib
- on December 20, 2017 for the adjuvant treatment of patients with melanoma with lymph node involvement or in patients with metastatic disease who have undergone complete resection
- on May 20, 2021 as adjuvant treatment for completely resected esophageal cancer or cancer of the gastroesophageal junction (GEJ)
- EMA (EU)
- on June 19, 2015 for metastatic melanoma
- on July 20, 2015 for NSCLC
- on February 26, 2016 for advanced renal cell carcinoma
- on October 13, 2016 for relapsed or refractory cHL
- on June 2, 2017 for urothelial carcinoma
- Health Canada on September 25, 2015 for:
- Previously untreated, unresectable or metastatic melanoma of the BRAF V600 wild type
- unresectable or metastatic melanoma and disease progression after ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor
- Melanoma with regional lymph node involvement, transit metastases/satellites without metastatic nodes or distant metastases, as adjuvant therapy after complete resection
- locally advanced or metastatic non-small cell lung cancer (NSCLC) with progression during or after platinum-based chemotherapy
- advanced or metastatic renal cell carcinoma (RCC) who have previously received anti-angiogenic therapy
- advanced or metastatic intermediate/low risk renal cell carcinoma (RCC) when combined with ipilimumab
- Recurrent or metastatic squamous cell cancer of the head and neck (SCCHN) that progresses during or after platinum-based therapy.
- TGA (Australia)
- on January 11, 2016 for metastatic melanoma and NSCLC and later for advanced clear cell renal cell carcinoma and relapsed or refractory cHL.
- Medsafe (New Zealand) on April 28, 2016 for:
- unresectable or metastatic melanoma, or melanoma with lymph node involvement or metastatic disease where complete resection has been performed.
- locally advanced or metastatic non-small cell lung cancer (NSCLC) with progression during or after prior chemotherapy
- Previously untreated advanced renal cell carcinoma with intermediate/low risk.
- Relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous stem cell transplantation and treatment with brentuximab vedotin
- Recurrent or metastatic squamous cell carcinoma of the head and neck in adults whose disease progresses during or after platinum-based therapy
- locally advanced inoperable or metastatic urothelial carcinoma after prior platinum-based therapy
- Liver cell carcinoma after previous sorafenib therapy.
How do I take Opdivo (nivolumab)?
The recommended therapy varies depending on the indication and whether nivolumab is used alone or in combination with other therapies. Detailed information on the dosage and administration of nivolumab for some of the approved countries can be found in the official prescribing information in our reference area.
Note: Ask your doctor about an individual dosage.
Are there any known side effects of Opdivo (nivolumab)?
Common side effects
The most common side effects were:
- fatigue
- rash
- Musculoskeletal pain
- Diarrhea
- Nausea.
| Quantity |
40 mg/4 mL ,100 mg/10 mL |
|---|
Shipping and delivery
All orders will only be shipped after payment confirmation. Please enter your shipping details and select the payment method that suits you best.
Shipping costs:
You should always be clearly informed about the total price of your purchase, including delivery and any other associated costs.
You must explicitly agree to any additional charges, for example, if the retailer offers express shipping or gift wrapping.
Damaged Goods:
The retailer is responsible for all damage to the product, from shipping to receipt.
If you have purchased an item that does not match the advertised product in appearance or function, you have the right to request a repair, a replacement, or, if neither of these is possible, a refund.
- Non-delivery:
If you have not received the product within 30 days or by the agreed date, you must notify the seller and grant them a reasonable extension of the delivery period.
For example, if the seller informs you of a one-week delay due to problems with their suppliers, it seems reasonable to grant them this additional week. If, despite the extension, the seller still fails to fulfill their obligation to deliver, you have the right to withdraw from the contract and receive an immediate refund.
Related products
Buy Darzalex (Daratumumab)
Who is Darzalex (daratumumab) suitable for?
Darzalex (daratumumab) is indicated for patients with:-
Newly diagnosed multiple myeloma for which autologous stem cell transplantation is not an option (first-line treatment). For this indication, it is used in combination with bortezomib, melphalan, and prednisone.
-
Patients with multiple myeloma who have received at least one prior therapy (second-line treatment). For this indication, it is used in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone.
-
Patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor (third-line therapy). For this indication, it is used in combination with pomalidomide and dexamethasone.
-
Multiple myeloma patients who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent, or who are doubly refractory to a PI and an immunomodulatory agent (fourth-line treatment). For this indication, it is used as monotherapy.
Buy Ibrance (Palbociclib)
What is Ibrance (palbociclib) for?
Palbociclib is indicated for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. It is indicated in combination with an aromatase inhibitor (hormone therapy) as initial endocrine-based therapy in postmenopausal women or with fulvestrant in women with disease progression after endocrine therapy.How does Ibrance (palbociclib) work?
Palbociclib is an inhibitor of cyclin-dependent kinase (CDK) 4 and 6.
Before a cell can divide, it must go through four phases. The first phase is a growth phase (G1 phase), the second a synthesis phase (S phase), the third another growth phase (G2 phase), and the final phase, in which the cell divides (M phase). Cancer cells divide extremely rapidly and pass through these four phases quickly. Palbociclib blocks the transition from the first G1 phase to the second S phase. This occurs by inhibiting cyclin-dependent kinases 4 and 6 (CDK4 and CDK6) – two proteins involved in entering the S phase [1] .
Buy Kadcyla (Trastuzumab Emtansine)
Buy Keytruda (Pembrolizumab)
Buy Perjeta (Pertuzumab)
What is Perjeta (pertuzumab) for?
Perjeta (pertuzumab) is indicated for the treatment of HER2-positive breast cancer in patients with metastatic cancer or as neoadjuvant treatment for patients with locally advanced, inflammatory or early breast cancer as part of a complete early breast cancer treatment regimen.
Buy Tecentriq (atezolizumab)
Reviews
There are no reviews yet.